Biocon Limited has informed the Exchange that Record date for the purpose of Dividend is 04-Jul-2025.

Corporate Actions View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹333.50

prior close

₹333.50

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.0%-0.8% vs market

Pharmaceuticals peers, median of 146sector-0.2%-0.6% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+1.3

15m

+1.2

30m

+1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8+0.0-0.8-0.2-0.6

Next day

-1.6+3.8-5.4+2.5-4.1

-1.0+4.0-5.0+4.0-5.0

+1.4+5.3-3.9+4.4-3.0

+1.3+6.1-4.8+5.1-3.8

+1.6+7.0-5.4+5.5-3.8

-0.1+5.5-5.6+5.5-5.6

15d

+0.3+7.8-7.5+7.3-7.1

+1.3+11.8-10.6+7.9-6.6

+12.2+11.7+0.6+8.7+3.5

+2.4+7.1-4.7+3.1-0.6

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 146Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon's board met on May 8, 2025 and approved audited financial results for Q4 and FY ended March 31, 2025. On a consolidated basis, FY25 revenue from operations rose to Rs. 15,262 crore from Rs. 14,756 crore in FY24, while net profit grew to Rs. 1,429 crore from Rs. 1,298 crore. Q4 FY25 was strong with revenue of Rs. 4,417 crore (up ~13% YoY) and net profit of Rs. 459 crore (more than double YoY). The board recommended a final dividend of Rs. 0.50 per share (10% on face value of Rs. 5), with record date set for July 4, 2025, subject to shareholder approval at the AGM on August 8, 2025. Ms. Naina Lal Kidwai was re-appointed as Independent Director for a second 5-year term, and V. Sreedharan & Associates was appointed as Secretarial Auditors for 5 years.

Likely market impact

The strong Q4 and full-year performance, with consolidated profit growth of about 10% for the full year and a doubling in Q4, is positive for shareholders. The dividend of Rs. 0.50 per share is modest given the share price, so it is unlikely to be a major catalyst for the stock, but the operational results and refinancing of subsidiary debt could support sentiment.